Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity-Reference-Cited by-同舟云学术

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

Published:2019-01-10 Issue:3 Volume:62 Page:1203-1217
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nirogi Ramakrishna¹^ORCID,Shinde Anil¹,Mohammed Abdul Rasheed¹,Badange Rajesh Kumar¹,Reballi Veena¹,Bandyala Thrinath Reddy¹,Saraf Sangram Keshari¹,Bojja Kumar¹,Manchineella Sravanthi¹,Achanta Pramod Kumar¹,Kandukuri Kiran Kumar¹,Subramanian Ramkumar¹,Benade Vijay¹,Palacharla Raghava Choudary¹,Jayarajan Pradeep¹,Pandey Santoshkumar¹,Jasti Venkat¹

Affiliation:

1. Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India

Funder

Suven Life Sciences Ltd.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01280

Reference39 articles.

1. Narcolepsy